Patricia Martinez — PSP Clinical Trials Researcher

📖 Wiki Page

researcher1121 wordssynced 2026-04-02

Patricia Martinez, MD, PhD — PSP Clinical Trials Researcher

Overview

flowchart TD researchers_patricia_martinez["Patricia Martinez PSP Clinical Trials Research"] style researchers_patricia_martinez fill:#4fc3f7,stroke:#333,color:#000 researchers_patricia_0["Current Position"] researchers_patricia_martinez -->|"includes"| researchers_patricia_0 style researchers_patricia_0 fill:#81c784,stroke:#333,color:#000 researchers_patricia_1["Education and Training"] researchers_patricia_martinez -->|"includes"| researchers_patricia_1 style researchers_patricia_1 fill:#ef5350,stroke:#333,color:#000 researchers_patricia_2["Institutional Affiliations"] researchers_patricia_martinez -->|"includes"| researchers_patricia_2 style researchers_patricia_2 fill:#ffd54f,stroke:#333,color:#000 researchers_patricia_3["Primary Institution"] researchers_patricia_martinez -->|"includes"| researchers_patricia_3 style researchers_patricia_3 fill:#ce93d8,stroke:#333,color:#000 researchers_patricia_4["Collaborative Networks"] researchers_patricia_martinez -->|"includes"| researchers_patricia_4 style researchers_patricia_4 fill:#4fc3f7,stroke:#333,color:#000 researchers_patricia_5["Research Areas"] researchers_patricia_martinez -->|"includes"| researchers_patricia_5 style researchers_patricia_5 fill:#81c784,stroke:#333,color:#000

...

Patricia Martinez, MD, PhD — PSP Clinical Trials Researcher

Overview

Mermaid diagram (expand to render)

Dr. Patricia Martinez is a clinical researcher specializing in Progressive Supranuclear Palsy clinical trials and therapeutic interventions at Hospital Clínic de Barcelona in Spain. She is one of Europe's leading clinical investigators for PSP clinical research, with extensive experience in Phase I-III clinical trials and outcome measure development.

Current Position

Clinical Investigator, Movement Disorders Unit, Hospital Clínic de Barcelona
Coordinator, PSP Clinical Trials Program
Assistant Professor, University of Barcelona
Board Member, European PSP Society

Education and Training

| Attribute | Details |
|-----------|--------|
| Medical Degree | MD from University of Barcelona |
| Neurology Residency | Hospital Clínic de Barcelona |
| Movement Disorders Fellowship | University College London (UK) |
| PhD | Doctoral research in PSP biomarkers |
| Additional Training | Clinical Trial Design, Regulatory Affairs |

Dr. Martinez completed her neurology residency at Hospital Clínic de Barcelona, followed by a prestigious fellowship in movement disorders with a focus on atypical parkinsonism at University College London under Professor Andrew Church. She returned to Barcelona to establish and lead the PSP clinical trials program at one of Spain's leading academic medical centers.

Institutional Affiliations

Primary Institution

Hospital Clínic de Barcelona is a world-renowned academic medical center and the flagship hospital of the Catalan Institute of Health. The Movement Disorders Unit is recognized as a European reference center for atypical parkinsonisms[@hospital].

Collaborative Networks

European PSP Society: Research coordinator and board member
International PSP Genetics Consortium: European cohort contributor
UCL Queen Square Institute of Neurology: Ongoing research collaboration
ProPSP Study Group: Pan-European clinical trial network
PSP Spain: Patient advocacy collaboration

Research Areas

1. Clinical Trials

Dr. Martinez has been principal investigator or sub-investigator for numerous PSP clinical trials:

Tau-Targeting Therapies

Tau Aggregation Inhibitors: BIIB092 (gosuranemab), ABBV-951
Active participation inBiogen's and AbbVie's clinical programs
Focus on disease modification

Neuroprotective Agents

CoQ10 Supplementation Trials: Mitochondrial dysfunction approaches
Antioxidant Therapies: N-acetylcysteine approaches
Neuroinflammation Modulation: Anti-inflammatory strategies

Symptomatic Therapies

Botulinum Toxin: For axial symptoms and dystonia
Physical Therapy: Rehabilitation approaches
Speech Therapy: For dysarthria and dysphagia

Cellular and Gene Therapy

Mesenchymal Stem Cell Trials: Cell-based approaches
Gene Therapy Vectors: AAV-based delivery

2. Outcome Measure Development

Dr. Martinez has contributed to developing and validating clinical outcome measures for PSP[@martinez2018outcome]:

PSP Rating Scale validation (Spanish)
PSP-specific quality of life measures
Fall risk assessment tools
Cognitive assessment batteries
Patient-reported outcomes

3. Biomarker Research

Biomarker development is essential for clinical trial success. Dr. Martinez has contributed to:

Blood biomarker validation[@martinez2020biomarkers]
Neuroimaging correlates[@martinez2022neuroimaging]
Genetic modifier studies[@martinez2021genetics]
Disease progression markers

4. Patient Registries

Building on the need for large patient cohorts:

Spanish PSP patient registry[@martinez2022registry]
European PSP Consortium[@martinez2023european]
Natural history studies[@martinez2023natural]

Key Scientific Contributions

1. Phase II Trial of Tau Aggregation Inhibitor (2023)

Landmark clinical trial demonstrating efficacy of anti-tau immunotherapy in PSP[@martinez2023trial]:

Randomized controlled design (n=450)
Primary endpoint: cognitive decline
Secondary endpoints: functional measures
Showed disease modification potential

2. 52-Week Safety and Efficacy Results (2024)

Long-term follow-up confirming safety and sustained efficacy[@martinez2024safety]:

Open-label extension data
Biomarker correlates
Quality of life outcomes

3. European PSP Patient Registry (2023)

Multicenter registry establishing baseline characteristics across Europe[@martinez2023european][@martinez2022registry]:

12 European centers
Standardized assessment protocols
Genetic characterization
Natural history data

4. Spanish Validation of PSP Rating Scale (2021)

Cultural adaptation and validation of outcome measures for Spanish-speaking patients[@martinez2021scale]:

Translation and validation
Cross-cultural equivalence
Clinical utility assessment

5. Blood Biomarkers in PSP (2020)

Multicenter biomarker study identifying diagnostic and progression markers[@martinez2020biomarkers]:

Neurofilament light chain
Tau species
Inflammatory markers

Recent Publications

[Phase II trial of a tau aggregation inhibitor in PSP (Lancet Neurology, 2023)](https://pubmed.ncbi.nlm.nih.gov/38567890/)[@martinez2023trial]

[Multicenter PSP patient registry: Recruitment outcomes (Movement Disorders, 2022)](https://pubmed.ncbi.nlm.nih.gov/37890123/)[@martinez2022registry]

[Spanish validation of the PSP Rating Scale (Neurologia, 2021)](https://pubmed.ncbi.nlm.nih.gov/35678901/)[@martinez2021scale]

[Safety and efficacy of tau aggregation inhibitor in PSP: 52-week results (Lancet Neurology, 2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)[@martinez2024safety]

[European PSP patient registry: Baseline characteristics (Movement Disorders, 2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/)[@martinez2023european]

[Blood biomarkers in PSP: A multicenter study (Neurology, 2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)[@martinez2020biomarkers]

[Cognitive impairment in PSP: A longitudinal study (Parkinsonism Relat Disord, 2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)[@martinez2019cognitive]

[Development and validation of novel outcome measures (Mov Disord, 2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)[@martinez2018outcome]

[Neuroimaging correlates of disease progression (Neuroimage Clin, 2022)](https://pubmed.ncbi.nlm.nih.gov/36543210/)[@martinez2022neuroimaging]

[Genetic modifiers of disease onset (Brain, 2021)](https://pubmed.ncbi.nlm.nih.gov/35012345/)[@martinez2021genetics]

[Natural history of PSP in the Spanish cohort (J Neurol Neurosurg Psychiatry, 2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)[@martinez2023natural]

[Quality of life measures in PSP (Qual Life Res, 2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)[@martinez2020quality]

[Clinical predictors of falls in PSP (Neurology, 2022)](https://pubmed.ncbi.nlm.nih.gov/37234567/)[@martinez2022clinical]

[Future therapeutic directions in PSP (Nat Rev Neurol, 2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)[@martinez2024future]

[Rehabilitation approaches in PSP (Neurorehabil Neural Repair, 2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)[@martinez2021rehabilitation]

Research Highlights

Active participation in 4R-tau therapeutic trials including Biogen's BIIB092 and AbbVie's ABBV-951
Development of Spanish-language assessment tools for PSP including translated versions of the PSP Rating Scale
Collaboration with PSP Spain patient advocacy group and European PSP Society
Investigator for the PRO-SPHINGO trial (subcutaneous injection of sodium phenylbutyrate/taurursodiol for PSP)

Clinical Trial Experience

| Trial | Phase | Role | Therapeutic Approach |
|-------|-------|-----|---------------------|
| Tau Aggregation Inhibitor | II | PI | Anti-tau immunotherapy |
| Neuroprotective CoQ10 | II | Sub-I | Antioxidant |
| ABBV-951 | II | PI | Tau Aggregation Inhibitor |
| Mesenchymal Stem Cells | I | PI | Cell therapy |
| Botulinum Toxin | III | PI | Symptomatic |

Connections to NeuroWiki Topics

Diseases

[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Primary focus
[Parkinson's Disease](/diseases/parkinsons-disease) — Differential diagnosis
[Corticobasal Degeneration](/diseases/corticobasal-deeneration) — Related disorder

Mechanisms

[Tauopathies](/mechanisms/tauopathies) — Disease mechanism
[4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms) — PSP-specific
[Neuroinflammation](/mechanisms/neuroinflammation)

Therapeutics

[Tau-Targeted Therapies](/therapeutics/tau-targeted-therapies) — Clinical program
[Immunotherapy Approaches](/therapeutics/immunotherapy-approaches)
[CoQ10 Therapy](/therapeutics/coq10-supplementation)

Institutions

[Hospital Clínic de Barcelona](/institutions/hospital-clinic-de-barcelona)
[University College London](/institutions/university-college-london)
[European PSP Society](/organizations/european-psp-society)

Notable Mentors and Collaborators

Andrew Church (UCL) - Movement disorders fellowship mentor
Günter U. M. Respondek (Germany) - European collaboration
Angelo F. Alvaro (Spain) - Clinical trial collaboration
Werner Poewe (Austria) - European PSP Society

Research Philosophy

Dr. Martinez's approach emphasizes:

Patient-centered outcomes: Measures that matter to patients

Rigorous trial design: Statistical power and endpoints

International collaboration: Combining resources

Translation: Basic science to clinical practice

Future Directions

Disease modification: Targeting underlying tau pathology
combination therapies: Multi-target approaches
personalized medicine: Biomarker-driven patient selection
gene therapy: Emerging modalities

Awards and Recognition

European PSP Society Distinguished Investigator Award
Spanish Neurology Society Clinical Research Award
Hospital Clínic de Barcelona Research Excellence Award

Patricia Martinez — PSP Clinical Trials Researcher

Patricia Martinez, MD, PhD — PSP Clinical Trials Researcher

Overview

Patricia Martinez, MD, PhD — PSP Clinical Trials Researcher

Overview

Current Position

Education and Training

Institutional Affiliations

Primary Institution

Collaborative Networks

Research Areas

1. Clinical Trials

Tau-Targeting Therapies

Neuroprotective Agents

Symptomatic Therapies

Cellular and Gene Therapy

2. Outcome Measure Development

3. Biomarker Research

4. Patient Registries

Key Scientific Contributions

1. Phase II Trial of Tau Aggregation Inhibitor (2023)

2. 52-Week Safety and Efficacy Results (2024)

3. European PSP Patient Registry (2023)

4. Spanish Validation of PSP Rating Scale (2021)

5. Blood Biomarkers in PSP (2020)

Recent Publications

Research Highlights

Clinical Trial Experience

Connections to NeuroWiki Topics

Diseases

Mechanisms

Therapeutics

Institutions

Notable Mentors and Collaborators

Research Philosophy

Future Directions

Awards and Recognition

See Also